Abbvie’s $1.4b bet on alzheimer’s biotech Aliada
Longevity Technology - 29-Oct-2024Aliada’s BBB technology aims to transform CNS drug delivery
AbbVie
Pharmaceutical research and development.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.
Visit website: https://www.abbvie.com/
Details last updated 05-Mar-2020
AbbVie News
Regenxbio-AbbVie gene therapy reduces eye injections for AMD patients
FierceBiotech - 17-Jan-2024Patients’ vision and retinal health remained stable after six months
Genetic profiling conducted by the mexico city prospective study highlights the value of genetic studies in diverse populations
Oxford Population Health - 11-Oct-2023Study reveals new insights into obesity, diabetes, and genetic diversity
Calico and AbbVie discover potential first-in-class cancer immunotherapy
Calico - 04-Oct-2023ABBV-CLS-484 enhances anti-tumor immunity and is currently in clinical trials
CollPlant gains $10m milestone from AbbVie to develop dermal and soft tissue filler
Longevity Technology - 04-Jul-2023Recombinant human collagen based fillers help advance the field regenerative aesthetics
AbbVie and Calico extends their collab up to 2025 with a $1 billion deal
FierceBiotech - 27-Jul-2021Supports ageing research and advancing early-stage projects to phase 2 trials over the next decade
Calico and AbbVie announced early-stage trials for new therapies
Calico - 03-Feb-2021Clinical trials in progress for potential targets of cancer and neurodegenerative diseases
Calico partners with AbbVie to develop a cancer drug
San Francisco Business Times - 19-Oct-2020Ex-Genentech CEO's drug company starts first clinical trial of cancer research
Alector’s AL002 shows early promise in Alzheimer’s treatment
Biospace - 09-Dec-2019First-in-human trial demonstrates safety and brain-target engagement for TREM2 therapy
Alector raises 133 million to tackle neurodegenerative diseases
Biospace - 25-Jul-2018Advancing immune-based therapies for alzheimer’s and dementia
Silicon Valley and rich people invest to slow down ageing and live longer
This Is Money - 17-Mar-2018All the money in the world to fight ageing and death
Doctors promoting treatments on social media fail to disclose ties to drug makers
STAT - 29-Feb-2016US physicians often fail to mention that they have accepted thousands of dollars from the compani...
Topics mentioned on this page:
Laboratory Automation
